Responses and Durability in NSCLC Treated with Pegilodecakin and Anti-Pd-1.

Edward B. Garon,Jeffrey Gary Schneider,Deborah J. L. Wong,Raid Aljumaily,Wolfgang Michael Korn,Jeffrey R. Infante,Manish R. Patel,Karen A. Autio,Kyriakos P. Papadopoulos,Aung Naing,Nashat Y. Gabrail,Pamela N. Munster,Jonathan Wade Goldman,Annie Hung,Peter Van Vlasselaer,Joseph Leveque,Martin Oft,David R. Spigel

Journal of clinical oncology（2018）

引用 2|浏览44

暂无评分

摘要

9018Background: Responses in NSCLC to agents targeting the PD-1/PD-L1 axis are correlated with PD-L1 expression by immunohistochemistry (IHC), tumor mutational burden (TMB), interferon associated m...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要